Biocept CFO resigns; interim replacement named
Biocept, a San Diego-based molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, has announced the voluntary resignation of Bill Kachioff, senior vice president and chief financial officer, to pursue other business opportunities. The company also announced that Mark G. Foletta has been appointed as the company’s interim chief financial officer, effective immediately.
Foletta was senior vice president and chief financial officer of Amylin Pharmaceuticals from 2000 through its acquisition by Bristol-Myers Squibb in 2012. At Amylin, he was responsible for capital formation, financial management, financial reporting and investor relations. He participated in the successful commercial launch of three novel pharmaceutical products as the company evolved from R&D to commercialization.
Previously, Foletta held a number of management positions with Intermark and Triton Group, and was an audit manager with Ernst & Young. Foletta serves on the boards of directors of publicly traded healthcare companies AMN Healthcare Services, Regulus Therapeutics and Dexcom, and privately held ViaCyte.